导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.02% | 2319/4773 |
| 近一周 | 0.96% | 774/5467 |
| 近一月 | -8.68% | 3969/5421 |
| 近一季 | 14.96% | 134/5238 |
| 近半年 | 1.41% | 1298/4931 |
| 近一年 | -12.84% | 3524/4400 |
| 近两年 | 28.05% | 2344/2954 |
| 近三年 | -2.10% | 1957/2253 |
| 成立以来 | 32.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.95% 2029/4961 |
-3.61% 3466/5312 |
- - |
- - |
| 2025 | 11.00% 2770/4813 |
2.69% 1292/3635 |
2.70% 1419/4076 |
20.34% 1992/4524 |
-12.54% 4260/4813 |
| 2024 | -12.38% 2375/3463 |
-12.88% 2470/2808 |
-9.36% 2353/3014 |
20.68% 681/3129 |
-8.06% 2828/3463 |
| 2023 | -10.38% 1300/2656 |
-0.77% 1826/2280 |
-7.75% 1902/2385 |
0.42% 368/2515 |
-2.51% 482/2655 |
| 2022 | -23.98% 1180/2207 |
-11.40% 508/1919 |
-2.48% 1778/2016 |
-19.97% 1825/2113 |
9.94% 189/2208 |
| 2021 | -13.49% 1136/1822 |
-3.20% 781/1255 |
9.10% 585/1330 |
-14.13% 1363/1466 |
-4.60% 1490/1822 |
| 2020 | 51.18% 160/1250 |
6.37% 42/1028 |
31.10% 42/1067 |
3.61% 975/1164 |
4.63% 834/1184 |
| 2019 | 31.96% 453/1092 |
29.02% 286/754 |
-8.15% 580/804 |
6.25% 131/850 |
4.81% 777/918 |
| 2018 | -25.64% 359/834 |
- - |
- - |
- - |
-20.15% 667/691 |
| 2017 | 20.59% 182/714 |
- - |
- - |
- - |
- - |
| 2016 | -10.71% 286/605 |
- - |
- - |
- - |
- - |
| 2015 | 40.63% 42/575 |
- - |
- - |
- - |
- - |
| 2014 | 5.28% 224/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华安中证细分医药ETF VS. 长安沪深300非周期A(740101) |